1. Home /
    2. Altai Protocol Library /
  2. New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Study:
  • Phase 3, randomized, double-blind, international trial
  • Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
  • Pembrolizumab (200 mg every 3 weeks) plus chemotherapy (n:566) or chemotherapy (n:281)
Efficacy:
  • mOS:23.0 m vs 16.1 months (HR:0.73, P=0.01) in CPS10 subgroup
  • mOS:17.6 m vs 16 months (HR:0.86, P=0.11) in CPS1 subgroup
  • ORR:52.7% vs 40.8 in CPS10 subgroup
Safety:
  • Any grade AEs: 96.3 vs 95% (anemia: 49.1% vs 45.9%; neutropenia 41.1% vs 38.1%; nausea 39.3% vs 41.3%)
  • Grade ≥3 AEs 68.1% vs 66.9%
  • Treatment related death: 2 patients and no
  • Immune-mediated adverse events 26.5% vs 6.4%

Engl J Med. 2022 Jul 21;387(3):217-226.

Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

https://doi.org/10.1056/nejmoa2202809

Reviewed by Hasan Çağrı Yıldırım, MD on Aug 16, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More